The Effect of Mesotherapy and Intra-articular Steroid Injection in Shoulder Pain

Haydarpasa Numune Training and Research Hospital84 enrolled

Overview

Patients with chronic shoulder pain will be divided randomly into mesotherapy and intra-articular steroid injection groups. Pain severity, range of motion and functional impairment will evaluated before treatment, 30 minutes and 4 weeks after the injections.

The study will include 84 patients aged 18-75 who applied to physical medicine and rehabilitation out-patient clinic with chronic shoulder pain between May and July 2024. Patients will be randomly divided into two groups: a mesotherapy group and steroid injection group, using the closed-envelope method. In the first group, a total of 3 sessions of mesotherapy are applied to the shoulder areas of the patients, 7 days apart. A single-session intra-articular 20 mg triamcinolone hexacetonide injection will be administered for patients in group 2. Pain severity, range of motion and functional impairment will evaluated before treatment, 30 minutes and 4 weeks after the injections.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Chronic Shoulder Pain

Interventions

MesotherapyPROCEDURE

A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.

Intra-articular steroid injectionPROCEDURE

Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Ages 18-75 2. Having shoulder pain for 6 months 3. VAS (Visual Analog Scale) \> 4 4. Patients who can receive verbal instructions and do not have cognitive deficits Exclusion Criteria: 1. Physical therapy applied to the shoulder area in the last 3 months 2. Having had a shoulder joint injection in the last 3 months 3. History of previous upper extremity surgery 4. History of drug allergy 5. Use of anticoagulant drugs (warfarin, low molecular weight heparin), patients with coagulation disorder 6. History of malignancy 7. Psychiatric illness 8. A rheumatological diagnosis such as Polymyalgia Rheumatica, Rheumatoid Arthritis, Ankylosing Spondylitis 9. Kidney failure 10. Liver disease 11. Heart failure 12. Pregnancy 13. Presence of infection, wound, allergy, burn-like lesions in the application area

Locations (1)

Health Science University Haydarpasa Numune Research and Training Hospital

Istanbul, Üsküdar, Turkey (Türkiye)

Outcomes

Primary Outcomes

VAS (Visual Analouge Scale)

Pain Severity evaluation ((0 (no pain)-10 (unbearable pain))

Time frame: Patients will be evaluated before treatment, 30 minutes and 4 weeks after the injections.

Shoulder Disability Questionnaire' (OSS) form

Functional Disability evaluation (0-100)

Time frame: Patients will be evaluated before treatment, 30 minutes and 4 weeks after the injections.

Goniometric shoulder range of motion

shoulder range of motion evaluation

Time frame: Patients will be evaluated before treatment, 30 minutes and 4 weeks after the injections.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.